A prospective, open-label, two-part study of treatment satisfaction with monthly oral Boniva in women with post-menopausal osteoporosis transitioned from weekly alendronate or risendronate.
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 19 Jun 2006 New trial record.